Boehringer Ingelheim and Zealand Pharma's obesity drug, Survodutide, shows no increased heart risk and significant weight loss in a late-stage trial, paving the way for global regulatory approval.
Divi's Laboratories announces the establishment of new Solid Phase Peptide Synthesis (SPPS) lines to cater to increasing ...
Eli Lilly's Phase 3 trial reveals that its weight-loss pill Foundayo effectively reduces obstructive sleep apnea severity, ...
AstraZeneca strengthens its vaccine pipeline by acquiring early-stage biotech firm Omniose, which specializes in developing ...
Mumbai: Drugmaker Lupin Limited ha launched raltegravir tablets in the US, following the approval of its Abbreviated New Drug ...
Zura Bio announces the failure of its experimental drug tibulizumab in a mid-stage trial for treating hidradenitis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results